China Approves World’s First CAR-T Therapy for Solid Tumors

China’s National Medical Products Administration (NMPA) has approved satricabtagene autoleucel (satri-cel, brand name Kailimei), the world’s first chimeric antigen receptor T-cell (CAR-T) therapy specifically designed to treat solid tumors. Developed by Shanghai-based CARsgen Therapeutics, the therapy is priced at 990,000 yuan ($146,491) per infusion and targets patients with advanced gastric cancer who have exhausted other treatment options, as reported by Caixin Global.

A Decade-Long Pursuit

The approval marks the culmination of more than a decade of research by CARsgen’s founder and CEO, Dr. Zonghai Li, who first identified CLDN18.2 as a viable target for CAR-T therapy around 2015. “In the blink of an eye, from first identifying CLDN18.2 as a reasonable CAR-T target to today’s global first solid tumor CAR-T drug approval, more than a decade has passed,” Dr. Li wrote in a WeChat Moments post following the approval.

CAR-T therapy works by extracting a patient’s own immune T-cells, genetically engineering them to recognize and attack cancer cells, and re-infusing them as “living drugs.” While this approach has been transformative for blood cancers such as leukemia and lymphoma, solid tumors have remained an elusive frontier due to biological barriers including the tumor microenvironment and difficulty selecting targets that avoid harming healthy tissue.

Clinical Evidence and Indication

Satri-cel is approved for patients with advanced, CLDN18.2-positive and HER2-negative gastric or gastroesophageal junction adenocarcinoma who have failed at least two prior lines of therapy. The approval is supported by data from a confirmatory Phase II randomized controlled trial (CT041-ST-01), the results of which were published in The Lancet in 2025.

Clinical trial data showed that patients receiving satri-cel achieved a median overall survival of 7.92 months compared to 5.49 months for standard care, representing a 31% reduction in the risk of death. Median progression-free survival was 3.25 months versus 1.77 months, a 63% reduction in the risk of disease progression or death.

“The approval of satri-cel provides us with a novel and effective therapeutic weapon,” said Professor Lin Shen of Peking University Cancer Hospital, the lead clinical investigator. “This product has brought clinically meaningful and significant benefits to such patients, with remarkable efficacy that is difficult to achieve with existing treatment modalities.”

A Paradigm Shift in Oncology

Prior to this approval, CAR-T therapies had only been approved for hematologic malignancies, which represent approximately 10% of all cancers. Solid tumors, including gastric, lung, liver, and pancreatic cancers, account for roughly 90% of cancer cases globally but have proven far more challenging to treat with cell therapies.

Dr. Zonghai Li described the approval as “an important milestone event marking the advancement of CAR-T cell therapy from hematologic malignancies to solid tumors.” Professor Lin Shen added that satri-cel “not only fills the gap in later-line treatment for advanced gastric cancer but also ushers in a new era of cellular therapy for solid tumors.”

Commercial Outlook and Competitive Landscape

CARsgen expects approximately 200 orders in 2026 and projects peak annual sales of 2 billion yuan within four to five years. The company’s manufacturing base in Shanghai’s Jinshan district holds China’s first Drug Manufacturing License for CAR-T cell therapy, built to GMP standards with vertically integrated production covering plasmid, lentiviral vector, and CAR-T cell manufacturing.

Satri-cel enters a competitive landscape that includes Astellas Pharma’s zolbetuximab, a monoclonal antibody also targeting CLDN18.2-positive gastric cancer that was approved in China in late 2024 at an annual cost of approximately 300,000 yuan ($41,379). While zolbetuximab is significantly cheaper, CAR-T therapy offers the potential for durable responses from a single infusion, whereas antibody treatments require ongoing administration.

Regulatory Recognition and Global Ambitions

Satri-cel has received multiple regulatory designations recognizing its potential, including Breakthrough Therapy and Priority Review status from China’s NMPA, RMAT and Orphan Drug designations from the U.S. Food and Drug Administration, and Orphan Medicinal Product designation and PRIME status from the European Medicines Agency. These designations signal CARsgen’s ambitions for global regulatory submissions in the United States, Europe, and other markets.

Implications and Outlook

The approval reinforces China’s growing leadership in cell and gene therapy innovation. According to the Shanghai Medical Products Administration, Shanghai holds one-third of China’s immune cell therapy clinical trial approvals and five of ten domestically approved cell and gene therapy products as of April 2026.

However, significant challenges remain. At 990,000 yuan per infusion, affordability and insurance coverage will be critical barriers in China, where gastric cancer is the fifth most common cancer with approximately 360,000 new cases and 260,000 deaths in 2022 alone. Additionally, the therapy’s autologous nature — requiring individualized manufacturing for each patient — limits scalability, and the clinical data shows survival improvement rather than curative potential in this late-line setting.

CARsgen is actively pursuing earlier lines of therapy, additional solid tumor indications including pancreatic and biliary tract cancers, and next-generation products such as allogeneic “off-the-shelf” CAR-T therapies. The company’s success in proving that the biological barriers of solid tumors can be overcome opens the door for other developers worldwide, potentially transforming the landscape of cancer immunotherapy for years to come.